Why the study?
Argatroban and bivalirudin are both used to treat heparin-induced thrombocytopenia, but it was unclear whether either agent offered an advantage in efficacy and maintaining targeted therapeutic anticoagulation.
Does argatroban improve time to therapeutic anticoagulation compared to bivalirudin in patients with suspected or confirmed heparin-induced thrombocytopenia?
Does argatroban improve time to therapeutic anticoagulation compared to bivalirudin in patients with suspected or confirmed heparin-induced thrombocytopenia?
Argatroban achieves initial therapeutic anticoagulation goals significantly faster than bivalirudin in patients with suspected or confirmed HIT.
Answers are grounded in this paper and cite their sources.
Argatroban may offer faster therapeutic anticoagulation in suspected HIT; leaves open effects on clinical outcomes.
Background: Argatroban and bivalirudin are direct thrombin inhibitors (DTIs) used for the treatment of heparin-induced thrombocytopenia (HIT). The purpose of this study was to determine whether either agent offered an advantage in efficacy and ability to remain within the targeted therapeutic anticoagulation range. Methods: This was a single-center, retrospective, observational cohort study at a large academic medical center. The primary efficacy outcome was time to therapeutic anticoagulation, defined as total number of hours to achieve 2 consecutive activated partial thromboplastin time (aPTT) values in goal range. Results: A total of 91 patients were included in the analysis. Average time to initial therapeutic anticoagulation was 4.71 hours and 9.8 hours for the argatroban and bivalirudin groups, respectively ( P < .01). Conclusions: Argatroban may be advantageous compared to bivalirudin in achieving initial therapeutic anticoagulation goals among patients with suspected or confirmed HIT.
No takes yet. Share an insight, caveat, or question.
Duewell et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: